267 Grant Street
Bridgeport, CT 06610
General Information
Objectives
-
Review staging system for classifying patients across the spectrum of CKM syndrome.
-
Understand the role of SGLT2 inhibitors and GLP1 receptor agonists as CKM therapies
-
Apply GLP1 receptor agonists as secondary preventive therapies for patients with ASCVD and obesity
Presentations and Speakers
Available Credits/Points
Disclosure Statements
Accreditation Statement
Test Information